Patents by Inventor Manuel Modiano
Manuel Modiano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11786504Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.Type: GrantFiled: September 9, 2021Date of Patent: October 17, 2023Assignee: TAPESTRY PHARMACEUTICALS, INC.Inventors: James D. McChesney, Gilles H. Tapolsky, David L. Emerson, John Marshall, Michael Kurman, Manuel Modiano
-
Publication number: 20210401797Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.Type: ApplicationFiled: September 9, 2021Publication date: December 30, 2021Applicant: TAPESTRY PHARMACEUTICALS, INC.Inventors: James D. MCCHESNEY, Gilles H. TAPOLSKY, David L. EMERSON, John MARSHALL, Michael KURMAN, Manuel MODIANO
-
Patent number: 11147793Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubules at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.Type: GrantFiled: October 12, 2018Date of Patent: October 19, 2021Assignee: TAPESTRY PHARMACEUTICALS, INC.Inventors: James D. McChesney, Gilles H. Tapolsky, David L. Emerson, John Marshall, Michael Kurman, Manuel Modiano
-
Publication number: 20190046501Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubules at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.Type: ApplicationFiled: October 12, 2018Publication date: February 14, 2019Applicant: TAPESTRY PHARMACEUTICALS, INC.Inventors: James D. McChesney, Gilles H. Tapolsky, David L. Emerson, John Marshall, Michael Kurman, Manuel Modiano
-
Patent number: 10143677Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.Type: GrantFiled: April 10, 2017Date of Patent: December 4, 2018Assignee: TAPESTRY PHARMACEUTICALS, INC.Inventors: James D. McChesney, Gilles H. Tapolsky, David L. Emerson, John Marshall, Michael Kurman, Manuel Modiano
-
Publication number: 20180117002Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.Type: ApplicationFiled: April 10, 2017Publication date: May 3, 2018Applicant: Tapestry Pharmaceuticals, Inc.Inventors: James D. McChesney, Gilles H. Tapolsky, David L. Emerson, John Marshall, Michael Kurman, Manuel Modiano
-
Publication number: 20170273942Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.Type: ApplicationFiled: April 10, 2017Publication date: September 28, 2017Applicant: Tapestry Pharmaceuticals, Inc.Inventors: James D. McChesney, Gilles H. Tapolsky, David L. Emerson, John Marshall, Michael Kurman, Manuel Modiano
-
Patent number: 9616043Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.Type: GrantFiled: September 11, 2015Date of Patent: April 11, 2017Assignee: Tapestry Pharmaceuticals, Inc.Inventors: James D. McChesney, Gilles Tapolsky, David L. Emerson, John Marshall, Michael Kurman, Manuel Modiano
-
Publication number: 20160113898Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.Type: ApplicationFiled: September 11, 2015Publication date: April 28, 2016Applicant: Tapestry Pharmaceuticals, Inc.Inventors: James D. McChesney, Gilles Tapolsky, David L. Emerson, John Marshall, Michael Kurman, Manuel Modiano
-
Patent number: 9132118Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.Type: GrantFiled: March 5, 2013Date of Patent: September 15, 2015Assignee: Tapestry Pharmaceuticals, Inc.Inventors: James D. McChesney, Gilles Tapolsky, David L. Emerson, John Marshall, Michael Kurman, Manuel Modiano
-
Patent number: 8552056Abstract: The present invention relates to a novel chemical compound of formula S-(1): for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.Type: GrantFiled: September 15, 2012Date of Patent: October 8, 2013Assignee: Tapestry Pharmaceuticals, Inc.Inventors: James D. McChesney, Gilles Tapolsky, David E. Emerson, John Marshall, Tauseef Ahmed, Allen Cohn, Michael Kurman, Manuel Modiano
-
Publication number: 20130253044Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.Type: ApplicationFiled: March 5, 2013Publication date: September 26, 2013Inventors: James D. McChesney, Gilles Tapolsky, David E. Emerson, John Marshall, Tauseef Ahmed, Allen Cohn, Michael Kurman, Manuel Modiano
-
Patent number: 8409574Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.Type: GrantFiled: August 20, 2010Date of Patent: April 2, 2013Inventors: James D. McChesney, Gilles Tapolsky, David E. Emerson, John Marshall, Tauseef Ahmed, Allen Cohn, Michael Kurman, Manuel Modiano
-
Publication number: 20130022668Abstract: The present invention relates to a novel chemical compound of formula S-(1): for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.Type: ApplicationFiled: September 15, 2012Publication date: January 24, 2013Applicant: TAPESTRY PHARMACEUTICALS, INC.Inventors: James D. McChesney, Gilles TAPOLSKY, David L. EMERSON, John MARSHALL, Tauseef AHMED, Allen COHN, Michael KURMAN, Manuel MODIANO
-
Patent number: 8273789Abstract: The present invention relates to a novel chemical compound of formula S-(1): for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.Type: GrantFiled: September 1, 2010Date of Patent: September 25, 2012Assignee: Tapestry Pharmaceuticals, Inc.Inventors: James D. McChesney, Gilles Tapolsky, David L. Emerson, John Marshall, Tauseef Ahmed, Allen Cohn, Michael Kurman, Manuel Modiano
-
Publication number: 20110318334Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.Type: ApplicationFiled: August 20, 2010Publication date: December 29, 2011Inventors: James D. McChesney, Gilles TAPOLSKY, David L. EMERSON, John MARSHALL, Tauseef AHMED, Allen COHN, Michael KURMAN, Manuel MODIANO
-
Publication number: 20110135712Abstract: The present invention relates to a novel chemical compound of formula S-(1): for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.Type: ApplicationFiled: September 1, 2010Publication date: June 9, 2011Applicant: TAPESTRY PHARMACEUTICALS, INC.Inventors: James D. McChesney, Gilles TAPOLSKY, David E. EMERSON, John MARSHALL, Tauseef AHMED, Allen COHN, Michael KURMAN, Manuel MODIANO